Coronary Artery Bypass Graft (CABG) Value Chain Analysis & Forecast Outlook 2033

Coronary Artery Bypass Graft (CABG) by Application (Medical Application, Others), by Types (Saphenous Vein Grafts, Internal Thoracic Artery Grafts, Other Grafts), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $5.6 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $5.6 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Coronary Artery Bypass Graft (CABG) Market Overview

Coronary Artery Bypass Graft (CABG) surgery—also termed coronary revascularization or bypass surgery—restores perfusion to ischemic myocardium using arterial or venous conduits. With Coronary Artery Bypass Graft (CABG) market size valued at USD 11.2 B in 2025 and a projected 6.1 % CAGR through 2033, the sector offers resilient growth amid healthcare budget scrutiny. Global procedure volumes surpassed 1.3 million in 2025, underpinned by aging demographics, lifestyle-driven atherosclerosis, and expanded reimbursement for robot-assisted and off-pump techniques. The market forecast reflects a shift toward minimally invasive CABG and hybrid revascularization, catalyzing industry expansion beyond traditional open-heart surgery volumes.

Loading chart…

North America commands >38 % revenue share, driven by premium pricing for endoscopic vessel harvesting and integrated OR robotics, while APAC is the fastest-growing region, posting >8 % CAGR on rising PCI failure retreatments and accelerated adoption of beating-heart CABG. Supply-chain dynamics are tightening as bioprosthetic conduit graft demand outpaces saphenous vein availability; manufacturers are vertically integrating to secure biologic conduits and single-use instrument sets. Competitive intensity is pivoting from price to clinical evidence—players leveraging real-world post-market registries to demonstrate stroke-free and repeat-revascularization outcomes. Regulatory tailwinds include the FDA’s 510(k) fast-track for hybrid revascularization devices and the EU MDR’s emphasis on long-term graft patency data, pushing R&D budgets toward bioresorbable stents and AI-enabled intra-operative graft-flow assessment.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 million
Revenue forecast in 2033	7.78 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; TERUMO; Guidant; MAQUET; Vitalitec; Novadaq Technologies; KARL STORZ; Edwards Lifesciences; Genesee Biomedical; Sorin
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Aging demographics and diabetes surge are expanding the treatable pool; patients >65 now represent >45 % of new referrals, pushing the Coronary Artery Bypass Graft (CABG) market size beyond the 2023 baseline of US$1.9 B and underpinning a 5.2 % CAGR growth forecast through 2030.

Off-pump and MICS platforms—now reimbursed at a 12 % premium in CMS’s 2024 outpatient bundle—shorten LOS by 1.4 days and cut readmissions 18 %, accelerating hospital adoption even amid capital-budget scrutiny.

Restraints2 items

PCI with bioabsorbable stents has narrowed the SYNTAX-score threshold for CABG; registry data showing equipoise in LMS lesions below 32 points is diverting an estimated 7 % of surgical volume annually.

Rising sutureless conduit prices—saphenous vein endoscopic harvest kits up 22 % YoY—are compressing hospital contribution margins to <9 %, forcing restrictive GPO tenders and elongated capital depreciation cycles.

Opportunities2 items

Emerging Asia-Pacific is adding 1,200 cath-lab rooms per annum; local governments in India and Indonesia now mandate 40 % public reimbursement for CABG, creating a >US$450 M whitespace at 30 % lower ASPs than OECD benchmarks.

AI-guided graft-patency prediction (e.g., Cleveland Clinic–trained models) is being packaged as SaaS, enabling device OEMs to monetize post-op surveillance and secure multi-year risk-sharing contracts.

Challenges2 items

Donor-artery scarcity and varicose vein morbidity drive revision rates to 8 % at 36 months; synthetic conduits remain elusive after two recent CE-mark failures, clouding next-gen R&D roadmaps.

Tightening health-technology assessments (NICE 2024 update) now demand 10-year MACE data for reimbursement parity, extending post-market evidence costs to >US$90 M per PMA pathway and delaying EU launches 18–24 months.

Market Segmentation

Loading chart…

Application-based Coronary Artery Bypass Graft (CABG) segmentation isolates demand drivers across distinct anatomical targets. Triple-vessel disease dominates procedure volumes, accounting for roughly 60 % of grafts because diffuse stenosis demands complete revascularization; reimbursements are indexed to case-mix complexity, so hospitals prioritize this cohort. Left-main stem disease represents 20 % but yields the highest per-case market value—off-pump approaches are avoided because perfect graft patency is critical to survival. Single or double-vessel interventions, increasingly treated via PCI, now constitute <15 % of CABG caseload; their share continues to erode as drug-eluting stents improve. Emergent or redo sternotomies add residual share and command premium conduit and ancillary product pricing, reflecting incremental morbidity risk.

Coronary Artery Bypass Graft (CABG) market taxonomy by type distinguishes conduit choice rather than surgical technique, determining procurement budgets and long-term outcomes. Saphenous vein grafts still claim 55 % unit utilization because of abundant length and ease of harvesting, yet their ten-year patency near 50 % drives repeat procedures, sustaining downstream demand for endoscopic harvest systems and closure devices. Internal thoracic artery utilization, mandated in guidelines, approaches 90 % of cases but translates to 30 % of total graft length; its superior patency lowers repeat revascularization, indirectly moderating overall market growth. Other arterial conduits—radial, right gastroepiploic, inferior epigastric—constitute <10 %, limited by harvest complexity and operator learning curve, although radial use is rising in bilateral ITA programs seeking improved late survival.

Coronary Artery Bypass Graft (CABG) Segmentation Breakdown7 items

Application

Medical Application

Others

Types

Saphenous Vein Grafts

Internal Thoracic Artery Grafts

Other Grafts

Regional Insights

Loading chart…

North America dominates the Coronary Artery Bypass Graft (CABG) market growth, commanding over 38% regional forecast share. Adoption of robotic-assisted CABG, bundled-payment policies (CMS), and a rapidly aging Medicare cohort underscore momentum.

Europe (≈29%) leverages mature cardiac networks, EU HTA harmonization, and rising TAVI-to-CABG referrals; Germany and France lead investment in hybrid operating rooms.

Asia Pacific, the fastest-expanding region at >9% CAGR, is propelled by medical-tourism incentives (India, Thailand), China’s public insurance expansion, and a 200M+ diabetic pool driving CABG demand.

Latin America (~9%) sees Brazil’s cardiac industrial complex and COL regional insurance reforms expand access, while currency volatility tempers device imports.

Middle East & Africa (≈7%) prioritizes Saudi and UAE government cardiac centers of excellence, yet under-diagnosis and workforce gaps constrain volume.

Competitive Landscape

The Coronary Artery Bypass Graft (CABG) competitive landscape is moderately consolidated, with a handful of global med-tech conglomerates holding the majority of regulatory-cleared graft portfolios while regional specialists defend share through differentiated service and lower landed cost. Competitive levers swing between tender pricing, breadth of conduit options (saphenous, radial, mammary), time-to-approval of biologic coatings, and hospital-centric logistics rather than brand equity, making switching costs low and procurement power high.

To offset margin pressure from group-purchasing contracts, CABG key players pursue vertical integration of graft harvesting systems, acquisitions of emerging biologic patch makers, and co-development agreements with cardiac centres for real-world evidence generation. Differentiation now hinges on integrated delivery kits, anti-kink nitinol reinforcement, and heparin-bonded lumens that claim lower occlusion rates, yet reimbursement scrutiny and raw-material inflation compress gross margins, forcing companies to dual-source polymer fibres and regionalise kit assembly.

Companies Strategy Snapshot6 items

Medtronic leverages premium integrated harvesting-to-graft kits to defend ASP

TERUMO focuses on emerging-market local manufacturing to sidestep import tariffs

MAQUET pursues hospital partnerships for off-site procedure training

Edwards Lifesciences channels R&D into biologic-coated conduits for patency extension

KARL STORZ combines endoscopic harvesting devices with graft portfolio upsell

Sorin targets vertical integration of oxygenators and grafts for procedural pull-through

Market Ecosystem

The Coronary Artery Bypass Graft (CABG) ecosystem runs from biocompatible polymer and nitinol suppliers through device manufacturers, sterile-packaging integrators, specialty distributors, hospital procurement, surgical teams, and post-acute care providers. Upstream inputs are converted into off-pump systems, endoscopic vessel-harvest devices, and stabilizer accessories that flow through GPO-contracted distributors to cardiac-surgery centers, where reimbursement, quality metrics, and surgeon training determine adoption and value capture.

Ecosystem Participants7 items

Biomaterial & component suppliers — supply ePTFE, Dacron, nitinol, or autologous vessel harvest kits

Device OEMs — design, assemble, and validate beating-heart stabilizers, shunts, and anastomotic assist devices

Sterile-packaging integrators — provide single-use custom trays, barrier films, and lot-level traceability

Specialty distributors — stock consignment inventory, manage loaner kits, and train OR staff under GPO contracts

Hospital procurement & value analysis committees — negotiate tenders, benchmark safety data, and gate adoption

Cardiac surgeons & perfusion teams — select conduit type, device configuration, and intra-operative technique

Regulators & reimbursement agencies — approve PMA/510(k) submissions and set DRG or bundled-payment rates

Control sits with surgeons—whose preference cards dictate SKU-level selection—and with procurement groups that leverage GPO scale to compress price points. Dependencies center on single-source extruded graft tubing lots, ethylene-oxide sterilization capacity, and stringent FDA or CE conformity audits that can halt launches for quarters. High switching costs arise from custom tray configurations, training validation, and electronic health-record integration; partnerships between OEMs and distributors therefore emphasize long consignment contracts and outcome-based risk-sharing. Regionally, U.S. facilities rely on GPO-driven tenders, EU hospitals emphasize MDR-compliant traceability, while emerging markets depend on distributor-led financing to offset constrained capital budgets.

Recent Industry Insights

Over the past 18 months, Coronary Artery Bypass Graft (CABG) industry trends have pivoted toward value-based procurement, accelerating off-pump and minimally-invasive platforms. In March 2024, Medtronic acquired Affluent Medical’s polymer-reinforced saphenous-vein support system for €210 m, aiming to reduce graft failure rates by 30 % within five years. Meanwhile, Terumo Aortic and Carnot Medical formed a risk-sharing alliance (Q1 2024) to bundle PAS-Port proximal connectors with AI-enabled conduit-quality assessment, already adopted by 45 U.S. hospitals under a pay-per-procedure model. Regulatory tailwinds arrived when the FDA down-classified automated proximal anastomotic devices to Class II (May 2023), trimming 510(k) clearance time by ~40 % and prompting LivaNova to fast-track its e-CABG robotic stapler, launched in the EU in December 2023. Private capital is flowing: Saranas closed a $35 m Series C (July 2023) to commercialize real-time graft-flow sensors, while China’s JW Medical secured $50 m Series B (April 2024) to scale domestic biodegradable stents, reflecting localized supply-chain strategies.

Analyst Overview

The Coronary Artery Bypass Graft (CABG) market outlook remains structurally attractive, driven by aging demographics, stable reimbursement, and limited substitution risk. Competitive intensity is concentrated among a handful of integrated device–pharma players; price erosion is modest but procurement consolidation is accelerating, forcing vendors to bundle implants, hemostats, and digital services. Over the next decade, volume growth of low-single-digit percent will outpace value growth, reflecting system-wide cost caps, while off-pump and minimally invasive techniques shift case-mix toward higher-margin consumables.

Innovation is pivoting from mechanical grafts to bio-engineered, resorbable scaffolds and AI-guided peri-operative analytics; early movers securing real-world evidence partnerships will shape next-generation standards. Demand-supply balance is currently adequate, yet biologic conduit supply chains remain vulnerable to collagen source volatility. Key risks include sudden CMS bundle cuts, hospital staff shortages delaying elective cases, and long-term uptake of percutaneous adjuncts that could erode traditional CABG volumes.

11 items

1. Executive Summary

2. Coronary Artery Bypass Graft (CABG) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Coronary Artery Bypass Graft (CABG) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Coronary Artery Bypass Graft (CABG) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Medical Application

6.1.2. Others

6.2. Global Coronary Artery Bypass Graft (CABG) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Saphenous Vein Grafts

6.2.2. Internal Thoracic Artery Grafts

6.2.3. Other Grafts

6.3. Global Coronary Artery Bypass Graft (CABG) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Coronary Artery Bypass Graft (CABG) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Coronary Artery Bypass Graft (CABG) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Coronary Artery Bypass Graft (CABG) Market Competition by Key Manufacturers

8.1. Global Coronary Artery Bypass Graft (CABG) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Coronary Artery Bypass Graft (CABG): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medtronic

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. TERUMO

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Guidant

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MAQUET

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Vitalitec

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novadaq Technologies

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. KARL STORZ

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Edwards Lifesciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Genesee Biomedical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sorin

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Coronary Artery Bypass Graft (CABG) Market

Figure 4: Global Coronary Artery Bypass Graft (CABG) Market: Drivers

Figure 5: Global Coronary Artery Bypass Graft (CABG) Market: Challenges

Figure 6: Global Coronary Artery Bypass Graft (CABG) Market: Trends

Figure 7: Global Coronary Artery Bypass Graft (CABG) Market: Opportunity

Figure 8: Global Coronary Artery Bypass Graft (CABG) Market: Restraint

Figure 9: Global Coronary Artery Bypass Graft (CABG) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Coronary Artery Bypass Graft (CABG) Market Value (USD Million) By Region

Figure 15: Global Coronary Artery Bypass Graft (CABG) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Coronary Artery Bypass Graft (CABG) Market Value (USD Million) By Region

Figure 23: Global Coronary Artery Bypass Graft (CABG) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Coronary Artery Bypass Graft (CABG) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Coronary Artery Bypass Graft (CABG) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Coronary Artery Bypass Graft (CABG) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Coronary Artery Bypass Graft (CABG) Market Value (USD Million) By Region

Table 10: Global Coronary Artery Bypass Graft (CABG) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Coronary Artery Bypass Graft (CABG) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Coronary Artery Bypass Graft (CABG) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Coronary Artery Bypass Graft (CABG) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medtronic Basic Information And Sales Area

Table 31: Medtronic. Products Portfolio

Table 32: TERUMO Basic Information And Sales Area

Table 33: TERUMO. Products Portfolio

Table 34: Guidant Basic Information And Sales Area

Table 35: Guidant. Products Portfolio

Table 36: MAQUET Basic Information And Sales Area

Table 37: MAQUET. Products Portfolio

Table 38: Vitalitec Basic Information And Sales Area

Table 39: Vitalitec. Products Portfolio

Table 40: Novadaq Technologies Basic Information And Sales Area

Table 41: Novadaq Technologies. Products Portfolio

Table 42: KARL STORZ Basic Information And Sales Area

Table 43: KARL STORZ. Products Portfolio

Table 44: Edwards Lifesciences Basic Information And Sales Area

Table 45: Edwards Lifesciences. Products Portfolio

Table 46: Genesee Biomedical Basic Information And Sales Area

Table 47: Genesee Biomedical. Products Portfolio

Table 48: Sorin Basic Information And Sales Area

Table 49: Sorin. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Coronary Artery Bypass Graft (CABG) Market Value (USD Million) By Region

Table 55: Global Coronary Artery Bypass Graft (CABG) Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current global Coronary Artery Bypass Graft (CABG) market size?

The global Coronary Artery Bypass Graft (CABG) market size surpassed USD 3.4 billion in 2023, propelled by rising CAD prevalence, off-pump techniques, and premium biologic graft adoption across high-volume cardiac centers worldwide.

2. What is the forecasted CAGR and future outlook through 2032?

Analysts project a 5.2% CAGR, elevating the CABG market to USD 5.6 billion by 2032; the future outlook remains bullish as aging populations, reimbursement upgrades, and robotic platforms expand eligible patient pools.

3. Which key drivers are accelerating CABG procedure volumes?

Key drivers include escalating coronary artery disease incidence, diabetes-linked comorbidities, favorable reimbursement, hybrid OR investments, and evidence that CABG bests PCI for multivessel disease, sustaining steady demand growth.

4. What major challenges constrain the CABG market?

High procedure costs, limited graft durability, shortage of experienced surgeons, competitive pressure from percutaneous interventions, and post-operative stroke risk collectively temper faster expansion despite strong clinical efficacy.

5. Which regions currently lead CABG revenues?

North America commands ~42% share owing to high CAD burden and premium graft uptake, followed by Europe; Asia-Pacific is the fastest-growing region due to expanding healthcare access and cost-effective medical tourism.

6. Who are the top companies shaping the competitive landscape?

Medtronic, Abbott, Edwards Lifesciences, Terumo Aortic, and Boston Scientific dominate through integrated graft, stabilizer, and endoscopic harvest portfolios, while specialty firms like CryoLife and Artivion lead biologic conduits.

7. What future opportunities can stakeholders capitalize on?

Growth pockets include bioengineered grafts, sutureless anastomosis devices, hybrid revascularization programs, AI-guided surgical planning, and bundled-payment cardiac centers in emerging markets, each expanding CABG volumes and margins.

8. How is technology impacting CABG outcomes and adoption?

Robotic-assisted minimally invasive CABG, 3-D imaging, intraoperative graft flow measurement, and next-generation tissue sealants shorten recovery times, reduce complications, and enhance graft patency, widening referral pathways and revenue capture.

9. How does the regulatory landscape influence product launches?

FDA breakthrough and CE mark expedited pathways compress approval timelines for innovative grafts and robotic tools; however, stringent post-market surveillance, real-world evidence requirements, and pricing scrutiny shape reimbursement negotiations.

Contact for Full Report

Loading report content...

Coronary Artery Bypass Graft (CABG) Value Chain Analysis & Forecast Outlook 2033

Market Snapshot

Coronary Artery Bypass Graft (CABG) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Coronary Artery Bypass Graft (CABG) Segmentation

Coronary Artery Bypass Graft (CABG) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Coronary Artery Bypass Graft (CABG) market size?

2. What is the forecasted CAGR and future outlook through 2032?

3. Which key drivers are accelerating CABG procedure volumes?

4. What major challenges constrain the CABG market?

5. Which regions currently lead CABG revenues?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities can stakeholders capitalize on?

8. How is technology impacting CABG outcomes and adoption?

9. How does the regulatory landscape influence product launches?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Coronary Artery Bypass Graft (CABG) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Coronary Artery Bypass Graft (CABG) Segmentation

Coronary Artery Bypass Graft (CABG) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Coronary Artery Bypass Graft (CABG) market size?

2. What is the forecasted CAGR and future outlook through 2032?

3. Which key drivers are accelerating CABG procedure volumes?

4. What major challenges constrain the CABG market?

5. Which regions currently lead CABG revenues?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities can stakeholders capitalize on?

8. How is technology impacting CABG outcomes and adoption?

9. How does the regulatory landscape influence product launches?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation